US 12,258,398 B2
Anti-Siglec-5 antibodies and methods of use thereof
Patricia Culp, Oakland, CA (US); Rashmi Bankoti, San Mateo, CA (US); Helen Lam, Union City, CA (US); and Arnon Rosenthal, Woodside, CA (US)
Assigned to ALECTOR LLC, South San Francisco, CA (US)
Appl. No. 17/263,534
Filed by Alector LLC, South San Francisco, CA (US)
PCT Filed Jul. 26, 2019, PCT No. PCT/US2019/043758
§ 371(c)(1), (2) Date Jan. 26, 2021,
PCT Pub. No. WO2020/023920, PCT Pub. Date Jan. 30, 2020.
Claims priority of provisional application 62/711,405, filed on Jul. 27, 2018.
Prior Publication US 2021/0395361 A1, Dec. 23, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 47/6849 (2017.08); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/20 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/56 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 34 Claims
 
1. An isolated monoclonal anti-Siglec-5 antibody, wherein the anti-Siglec-5 antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain comprises an HVR-L1, an HVR-L2, and an HVR-L3, and the heavy chain variable domain comprises an HVR-H1, an HVR-H2, and an HVR-H3, wherein:
(a) the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 103, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 127, the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 153, the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 20, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 39, and the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 70;
(b) the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 104, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 128, the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 154, the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 21, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 40, and the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 71;
(c) the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 111, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 133, the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 161, the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 26, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 46, and the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 77;
(d) the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 114, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 127, the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 153, the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 20, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 49, and the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 70;
(e) the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 115, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 128, the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 154, the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 21, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 50, and the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 71; or
(f) the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 111, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 133, the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 161, the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 26, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 51, and the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 77.